Article
Oral Baricitinib in the Treatment of Cutaneous Lichen Planus
2024-01-11
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of interferon (IFN)-γ, a cytokine implicated in the pathogenesis of LP. <h4>Methods</h4> In this phase II trial, twe...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1cc7bf06-74ab-546c-87c7-7471e716a8bd
- DOI
- 10.1101/2024.01.09.24300946
